mTOR inhibitors and surgical options serve distinct roles in managing conditions like subependymal giant cell astrocytomas (SEGAs) and other mTOR pathway-related tumours. The choice between these approaches depends on the tumour’s size, symptoms, and the patient’s overall condition.
